-
公开(公告)号：US06846815B2
公开(公告)日：2005-01-25
申请号：US10357240
申请日：2003-02-03
IPC分类号： A61K31/47 , A61K31/498 , A61P9/00 , A61P29/00 , A61P35/00 , A61P43/00 , C07D215/20 , C07D215/38 , C07D241/44 , C07D241/52 , C07D241/54 , C07D403/04 , C07D405/12 , A61K31/33 , A61K31/495 , C07D241/36 , C07D401/00
CPC分类号： C07D215/38 , C07D215/20 , C07D241/44 , C07D241/52 , C07D241/54 , C07D403/04 , C07D405/12
摘要： This invention is directed to quinoline/quinoxaline compounds which inhibit platelet-derived growth factor tyrosine kinase and/or Lck tyrosine kinase, to pharmaceutical compositions comprising these compounds, and to the use of these compounds for treating a patient suffering from or subject to disorders/conditions involving cellular differentiation, proliferation, extracellular matrix production or mediator release and/or T cell activation and proliferation.
-
2.发明授权Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase 失效抑制CSF-1R受体酪氨酸激酶的芳基和杂芳基喹唑啉化合物
公开(公告)号：US5714493A
公开(公告)日：1998-02-03
申请号：US652444
申请日：1996-06-04
申请人： Michael R. Myers , Alfred P. Spada , Martin P. Maguire , Paul E. Persons , Asher Zilberstein , Chin-Yi Jenny Hsu , Susan E. Johnson
发明人： Michael R. Myers , Alfred P. Spada , Martin P. Maguire , Paul E. Persons , Asher Zilberstein , Chin-Yi Jenny Hsu , Susan E. Johnson
IPC分类号： A61K31/5377 , C07C43/205 , C07C43/225 , C07C43/23 , C07D213/30 , C07D213/64 , C07D215/14 , C07D215/18 , C07D215/20 , C07D215/22 , C07D215/233 , C07D215/50 , C07D239/74 , C07D239/88 , C07D239/91 , C07D239/93 , C07D239/94 , C07D241/42 , C07D241/52 , C07D265/22 , C07D277/64 , C07D401/04 , C07D403/04 , C07D403/12 , C07D405/04 , C07D405/12 , C07D409/04 , C07D471/04 , A61K31/505
CPC分类号： C07D213/30 , A61K31/517 , A61K31/5377 , C07C43/2055 , C07C43/225 , C07C43/23 , C07D213/64 , C07D215/14 , C07D215/18 , C07D215/20 , C07D215/233 , C07D215/50 , C07D239/74 , C07D239/88 , C07D239/91 , C07D239/93 , C07D239/94 , C07D241/42 , C07D241/52 , C07D265/22 , C07D277/64 , C07D401/04 , C07D403/04 , C07D403/12 , C07D405/04 , C07D405/12 , C07D409/04 , C07D471/04
摘要： This invention relates to the treatment of intimation in a patient suffering from such disorder. More specifically, the invention relates to mono- and/or bicyclic aryl or heteroaryl quinazoline compounds in the treatment of inflammation.
摘要翻译： PCT No.PCT / US94 / 14180 Sec。 371日期1996年6月4日 102（e）日期1996年6月4日PCT 1994年12月8日PCT公布。 WO95 / 15758 PCT出版物 日期1996年6月15日本发明涉及患有这种病症的患者的暗示治疗。 更具体地，本发明涉及单和/或双环芳基或杂芳基喹唑啉化合物治疗炎症。
-
3.发明授权Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase 失效抑制EGF和/或PDGF受体酪氨酸激酶的芳基和杂芳基喹唑啉化合物
公开(公告)号：US5710158A
公开(公告)日：1998-01-20
申请号：US229886
申请日：1994-04-19
IPC分类号： A61K31/495 , A61K31/517 , A61K31/5377 , A61P19/00 , A61P35/00 , A61P37/00 , A61P39/00 , C07C43/205 , C07C43/225 , C07C43/23 , C07D213/30 , C07D213/64 , C07D215/14 , C07D215/18 , C07D215/20 , C07D215/22 , C07D215/233 , C07D215/50 , C07D239/74 , C07D239/88 , C07D239/91 , C07D239/93 , C07D239/94 , C07D241/42 , C07D241/52 , C07D265/22 , C07D277/64 , C07D401/04 , C07D403/04 , C07D403/12 , C07D405/04 , C07D405/12 , C07D409/04 , C07D471/04 , A61K31/505
CPC分类号： C07D213/30 , A61K31/517 , A61K31/5377 , C07C43/2055 , C07C43/225 , C07C43/23 , C07D213/64 , C07D215/14 , C07D215/18 , C07D215/20 , C07D215/233 , C07D215/50 , C07D239/74 , C07D239/88 , C07D239/91 , C07D239/93 , C07D239/94 , C07D241/42 , C07D241/52 , C07D265/22 , C07D277/64 , C07D401/04 , C07D403/04 , C07D403/12 , C07D405/04 , C07D405/12 , C07D409/04 , C07D471/04
摘要： This invention relates to the modulation and/or inhibition of cell signaling, cell proliferation, cell inflammatory response, the control of abnormal cell growth and cell reproduction. More specifically, this invention relates to the use of mono- and/or bicyclic aryl or heteroaryl quinazoline compounds in inhibiting cell proliferation, including compounds which are useful protein tyrosine kinase (PTK) inhibitors. The method of treating cell proliferation using said quinazoline compounds and their use in pharmaceutical compositions is described.
摘要翻译： 本发明涉及细胞信号调节和/或抑制，细胞增殖，细胞炎症反应，异常细胞生长和细胞繁殖的控制。 更具体地，本发明涉及单和/或双环芳基或杂芳基喹唑啉化合物在抑制细胞增殖中的用途，包括有用的蛋白酪氨酸激酶（PTK）抑制剂的化合物。 描述了使用所述喹唑啉化合物治疗细胞增殖的方法及其在药物组合物中的用途。
-
4.发明授权Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase 失效抑制EGF和/或PDGF受体酪氨酸激酶的双单和双环芳基和杂芳基化合物
公开(公告)号：US5646153A
公开(公告)日：1997-07-08
申请号：US439027
申请日：1995-05-11
IPC分类号： A61K31/495 , A61K31/517 , A61K31/5377 , C07C43/205 , C07C43/225 , C07C43/23 , C07D213/30 , C07D213/64 , C07D215/14 , C07D215/18 , C07D215/20 , C07D215/22 , C07D215/233 , C07D215/50 , C07D239/74 , C07D239/88 , C07D239/91 , C07D239/93 , C07D239/94 , C07D241/42 , C07D241/52 , C07D265/22 , C07D277/64 , C07D401/04 , C07D403/04 , C07D403/12 , C07D405/04 , C07D405/12 , C07D409/04 , C07D471/04 , A61K31/505 , A61K31/38 , A61K31/44 , A61K31/47
CPC分类号： C07D403/12 , A61K31/517 , A61K31/5377 , C07C43/2055 , C07C43/225 , C07C43/23 , C07D213/30 , C07D213/64 , C07D215/14 , C07D215/18 , C07D215/20 , C07D215/233 , C07D215/50 , C07D239/74 , C07D239/88 , C07D239/91 , C07D239/93 , C07D239/94 , C07D241/42 , C07D241/52 , C07D265/22 , C07D277/64 , C07D401/04 , C07D403/04 , C07D405/04 , C07D405/12 , C07D409/04 , C07D471/04
摘要： This invention relates to bis mono- and/or bicyclic aryl and/or heteroaryl compounds exhibiting protein tyrosine kinase inhibition activity. More specifically, it relates to the method of inhibiting abnormal cell proliferation in a patient suffering from a disorder characterized by such proliferation comprising the administration thereto of an EGF and/or PDGF receptor inhibiting effective amount of said bis mono- and/or bicyclic aryl and/or heteroaryl compound and to the preparation of said compounds and their use in pharmaceutical compositions used in this method.
摘要翻译： 本发明涉及显示蛋白酪氨酸激酶抑制活性的双单和/或双环芳基和/或杂芳基化合物。 更具体地，本发明涉及抑制患有以这种增殖为特征的病症的患者的异常细胞增殖的方法，其包括给予EGF和/或PDGF受体抑制有效量的所述双 - 单 - 和/或双环芳基和 /或杂芳基化合物，以及所述化合物的制备及其在该方法中使用的药物组合物中的用途。
-
5.发明授权Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases 失效抑制血小板衍生生长因子和/或p56lck酪氨酸激酶的喹啉和喹喔啉化合物公开(公告)号：US07550597B2
公开(公告)日：2009-06-23
申请号：US11043473
申请日：2005-01-25
IPC分类号： A61K31/33 , A61K31/495 , C07D241/36 , C07D401/00 , C07D215/38
CPC分类号： C07D215/38 , C07D215/20 , C07D241/44 , C07D241/52 , C07D241/54 , C07D403/04 , C07D405/12
摘要： This invention is directed to quinoline/quinoxaline compounds which inhibit platelet-derived growth factor tyrosine kinase and/or Lck tyrosine kinase, to pharmaceutical compositions comprising these compounds, and to the use of these compounds for treating a patient suffering from or subject to disorders/conditions involving cellular differentiation, proliferation, extracellular matrix production or mediator release and/or T cell activation and proliferation.
摘要翻译： 本发明涉及抑制血小板衍生生长因子酪氨酸激酶和/或Lck酪氨酸激酶的喹啉/喹喔啉化合物，包含这些化合物的药物组合物，以及这些化合物用于治疗患有或患有疾病/ 涉及细胞分化，增殖，细胞外基质产生或介体释放和/或T细胞活化和增殖的条件。
-
公开(公告)号：US06524347B1
公开(公告)日：2003-02-25
申请号：US09675741
申请日：2000-09-29
IPC分类号： A61K31498
CPC分类号： C07D215/38 , C07D215/20 , C07D241/44 , C07D241/52 , C07D241/54 , C07D403/04 , C07D405/12
摘要： This invention is directed to quinoline/quinoxaline compounds which inhibit platelet-derived growth factor tyrosine kinase and/or Lck tyrosine kinase, to pharmaceutical compositions comprising these compounds, and to the use of these compounds for treating a patient suffering from or subject to disorders/conditions involving cellular differentiation, proliferation, extracellular matrix production or mediator release and/or T cell activation and proliferation.
-
7.发明授权Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase 失效抑制EGF和/或PDGF受体酪氨酸激酶的双单和双环芳基和杂芳基化合物
公开(公告)号：US6057320A
公开(公告)日：2000-05-02
申请号：US881991
申请日：1997-06-25
IPC分类号： A61K31/495 , A61K31/517 , A61K31/5377 , C07C43/205 , C07C43/225 , C07C43/23 , C07D213/30 , C07D213/64 , C07D215/14 , C07D215/18 , C07D215/20 , C07D215/22 , C07D215/233 , C07D215/50 , C07D239/74 , C07D239/88 , C07D239/91 , C07D239/93 , C07D239/94 , C07D241/42 , C07D241/52 , C07D265/22 , C07D277/64 , C07D401/04 , C07D403/04 , C07D403/12 , C07D405/04 , C07D405/12 , C07D409/04 , C07D471/04
CPC分类号： C07D403/12 , A61K31/517 , A61K31/5377 , C07C43/2055 , C07C43/225 , C07C43/23 , C07D213/30 , C07D213/64 , C07D215/14 , C07D215/18 , C07D215/20 , C07D215/233 , C07D215/50 , C07D239/74 , C07D239/88 , C07D239/91 , C07D239/93 , C07D239/94 , C07D241/42 , C07D241/52 , C07D265/22 , C07D277/64 , C07D401/04 , C07D403/04 , C07D405/04 , C07D405/12 , C07D409/04 , C07D471/04
摘要： This invention relates to bis mono- and/or bicyclic aryl and/or heteroaryl compounds exhibiting protein tyrosine kinase inhibition activity. More specifically, it relates to the method of inhibiting abnormal cell proliferation in a patient suffering from a disorder characterized by such proliferation comprising the administration thereto of an EGF and/or PDGF receptor inhibiting effective amount of said bis mono- and/or bicyclic aryl and/or heteroaryl compound and to the preparation of said compounds and their use in pharmaceutical compositions used in this method.
摘要翻译： 本发明涉及显示蛋白酪氨酸激酶抑制活性的双单和/或双环芳基和/或杂芳基化合物。 更具体地，本发明涉及抑制患有以这种增殖为特征的病症的患者的异常细胞增殖的方法，其包括给予EGF和/或PDGF受体抑制有效量的所述双 - 单 - 和/或双环芳基和 /或杂芳基化合物，以及所述化合物的制备及其在该方法中使用的药物组合物中的用途。
-
公开(公告)号：US5795889A
公开(公告)日：1998-08-18
申请号：US386271
申请日：1995-02-09
IPC分类号： A61K31/495 , A61K31/517 , A61K31/5377 , C07C43/205 , C07C43/225 , C07C43/23 , C07D213/30 , C07D213/64 , C07D215/14 , C07D215/18 , C07D215/20 , C07D215/22 , C07D215/233 , C07D215/50 , C07D239/74 , C07D239/88 , C07D239/91 , C07D239/93 , C07D239/94 , C07D241/42 , C07D241/52 , C07D265/22 , C07D277/64 , C07D401/04 , C07D403/04 , C07D403/12 , C07D405/04 , C07D405/12 , C07D409/04 , C07D471/04 , A61K31/47 , A61K31/535 , C07D215/16
CPC分类号： C07D403/12 , A61K31/517 , A61K31/5377 , C07C43/2055 , C07C43/225 , C07C43/23 , C07D213/30 , C07D213/64 , C07D215/14 , C07D215/18 , C07D215/20 , C07D215/233 , C07D215/50 , C07D239/74 , C07D239/88 , C07D239/91 , C07D239/93 , C07D239/94 , C07D241/42 , C07D241/52 , C07D265/22 , C07D277/64 , C07D401/04 , C07D403/04 , C07D405/04 , C07D405/12 , C07D409/04 , C07D471/04
摘要： This invention relates to bis mono- and/or bicyclic aryl and/or heteroaryl compounds exhibiting protein tyrosine kinase inhibition activity. More specifically, it relates to the method of inhibiting abnormal cell proliferation in a patient suffering from a disorder characterized by such proliferation comprising the administration thereto of an EGF and/or PDGF receptor inhibiting effective amount of said bis mono- and/or bicyclic aryl and/or heteroaryl compound and to the preparation of said compounds and their use in pharmaceutical compositions used in this method.
-
9.发明授权Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase 失效抑制EGF和/或PDGF受体酪氨酸激酶的双单和双环芳基和杂芳基化合物
公开(公告)号：US5656643A
公开(公告)日：1997-08-12
申请号：US385258
申请日：1995-02-08
IPC分类号： A61K31/4375 , A61K31/47 , A61K31/4709 , A61K31/4725 , A61K31/498 , A61K31/517 , C07D213/64 , C07D215/20 , C07D401/04 , C07D409/04 , C07D401/06 , C07D401/12
CPC分类号： C07D213/64 , A61K31/4375 , A61K31/47 , A61K31/4709 , A61K31/4725 , A61K31/498 , A61K31/517 , C07D215/20 , C07D401/04 , C07D409/04
摘要： This invention relates to bis mono- and/or bicyclic aryl and/or heteroaryl compounds exhibiting protein tyrosine kinase inhibition activity. More specifically, it relates to the method of inhibiting abnormal cell proliferation in a patient suffering from a disorder characterized by such proliferation comprising the administration thereto of an EGF and/or PDGF receptor inhibiting effective amount of said bis mono- and/or bicyclic aryl and/or heteroaryl compound and to the preparation of said compounds and their use in pharmaceutical compositions used in this method.
摘要翻译： 本发明涉及显示蛋白酪氨酸激酶抑制活性的双单和/或双环芳基和/或杂芳基化合物。 更具体地，本发明涉及抑制患有以这种增殖为特征的病症的患者的异常细胞增殖的方法，其包括给予EGF和/或PDGF受体抑制有效量的所述双 - 单 - 和/或双环芳基和 /或杂芳基化合物，以及所述化合物的制备及其在该方法中使用的药物组合物中的用途。
-
公开(公告)号：US6159978A
公开(公告)日：2000-12-12
申请号：US198716
申请日：1998-11-24
IPC分类号： A61K31/47 , A61K31/498 , A61P9/00 , A61P29/00 , A61P35/00 , A61P43/00 , C07D215/20 , C07D215/38 , C07D241/44 , C07D241/52 , C07D241/54 , C07D403/04 , C07D405/12 , C07D241/36
CPC分类号： C07D215/38 , C07D215/20 , C07D241/44 , C07D241/52 , C07D241/54 , C07D403/04 , C07D405/12
摘要： This invention is directed to quinoline/quinoxaline compounds which inhibit platelet-derived growth factor tyrosine kinase and/or Lck tyrosine kinase, to pharmaceutical compositions comprising these compounds, and to the use of these compounds for treating a patient suffering from or subject to disorders/conditions involving cellular differentiation, proliferation, extracellular matrix production or mediator release and/or T cell activation and proliferation.
-
-
-
-
-
-
-
-
-
搜索结果
30 条记录 (耗时 0.028 秒)
